Augmedix (Augmedix) Change In Receivables : $-3.93 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Augmedix Change In Receivables?

Augmedix's change in receivables for the quarter that ended in Mar. 2024 was $-1.48 Mil. It means Augmedix's Accounts Receivable increased by $1.48 Mil from Dec. 2023 to Mar. 2024 .

Augmedix's change in receivables for the fiscal year that ended in Dec. 2023 was $-2.40 Mil. It means Augmedix's Accounts Receivable increased by $2.40 Mil from Dec. 2022 to Dec. 2023 .

Augmedix's Accounts Receivable for the quarter that ended in Mar. 2024 was $9.98 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Augmedix's Days Sales Outstanding for the three months ended in Mar. 2024 was 67.60.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Augmedix's liquidation value for the three months ended in Mar. 2024 was $3.01 Mil.

Augmedix Change In Receivables Historical Data

The historical data trend for Augmedix's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix Change In Receivables Chart

Augmedix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.13

-0.40

-4.43

0.79

-2.40

Augmedix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													0.06	-3.16	-0.02	0.73	-1.48

Augmedix Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.93 Mil.

Augmedix (NAS:AUGX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Augmedix's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	9.979	/	13.471	*	91
=	67.60

2. In Ben Graham's calculation of liquidation value, Augmedix's accounts receivable are only considered to be worth 75% of book value:

Augmedix's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	37.301	-	41.777	+	0.75 * 9.979	+	0.5 * 0
=	3.01

Augmedix Change In Receivables Related Terms

Thank you for viewing the detailed overview of Augmedix's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Augmedix (Augmedix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104

Website

https://www.augmedix.com

Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.

Executives

Paul Ginocchio	officer: Chief Financial Officer	C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor	director	5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p.	director, 10 percent owner	ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner	director	C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly	director	C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc	director, 10 percent owner	ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo	director	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins	officer: Chief Revenue Officer	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber	officer: CHIEF OPERATING OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil	officer: CHIEF STRATEGY OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris	director, officer: PRESIDENT, CEO, AND SECRETARY	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee	officer: CHIEF TECHNOLOGY OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw	director	4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian	director, 10 percent owner	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103